Abstract
Success of nucleic acid based therapies often depends on target-cell specific delivery of genetic materials such as plasmid DNA, antisense oligonucleotides or small interfering RNA. Such extracellular targeting strategies include the incorporation of hydrophilic shielding domains into nucleic acid carriers which protects them from unspecific interactions with non-target tissues (passive targeting), and the inclusion of targeting moieties which allows recognition of targetspecific cellular receptors (active targeting). Furthermore physical targeting methods such as magnetofection, electroporation or by photochemical means have been used to enhance efficiency of nucleic acid transfer. For optimum efficacy, extracellular targeting concepts are combined with programmed bioresponsive carrier chemistry which confers to the formulation stability during extracellular delivery but controlled disassembly and nucleic acid release after reaching the target cell.
Keywords: Bioresponsive systems, gene therapy, ligands, lipoplexes, nucleic acids, polyplexes, siRNA, targeting
Current Gene Therapy
Title: Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Volume: 8 Issue: 5
Author(s): Alexander Philipp, Martin Meyer and Ernst Wagner
Affiliation:
Keywords: Bioresponsive systems, gene therapy, ligands, lipoplexes, nucleic acids, polyplexes, siRNA, targeting
Abstract: Success of nucleic acid based therapies often depends on target-cell specific delivery of genetic materials such as plasmid DNA, antisense oligonucleotides or small interfering RNA. Such extracellular targeting strategies include the incorporation of hydrophilic shielding domains into nucleic acid carriers which protects them from unspecific interactions with non-target tissues (passive targeting), and the inclusion of targeting moieties which allows recognition of targetspecific cellular receptors (active targeting). Furthermore physical targeting methods such as magnetofection, electroporation or by photochemical means have been used to enhance efficiency of nucleic acid transfer. For optimum efficacy, extracellular targeting concepts are combined with programmed bioresponsive carrier chemistry which confers to the formulation stability during extracellular delivery but controlled disassembly and nucleic acid release after reaching the target cell.
Export Options
About this article
Cite this article as:
Philipp Alexander, Meyer Martin and Wagner Ernst, Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations, Current Gene Therapy 2008; 8 (5) . https://dx.doi.org/10.2174/156652308786071023
DOI https://dx.doi.org/10.2174/156652308786071023 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Inhibition of Early Biochemical Defects in Prodromal Huntington’s disease by Simultaneous Activation of Nrf2 and Elevation of Multiple Micronutrients
Current Aging Science Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
Current Medicinal Chemistry - Central Nervous System Agents Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?
Current Medicinal Chemistry Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Insulin Modulates <i>In Vitro Secretion</i> of Cytokines and Cytotoxins by Human Glial Cells
Current Alzheimer Research Anti-Aggregating Antibodies, a New Approach Towards Treatment of Conformational Diseases
Current Medicinal Chemistry Anti-Degenerative Effect of Melatonin on Intervertebral Disc: Protective Contribution against Inflammation, Oxidative Stress, Apoptosis, and Autophagy
Current Drug Targets Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)
Current Medicinal Chemistry Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§
Current Medicinal Chemistry